Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

December 12, 2024 9:00 AM

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today provided an overview of the data from the poster presentation conducted yesterday, December 11, 2024, at the San Antonio Breast Cancer Symposium (SABCS) about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial, which indicates that crofelemer achieved statistically...

Read more

Haven House Luxury Sober Living Nominated for Best Luxury Sober Living 2024 in Los Angeles

December 12, 2024 9:00 AM

Haven House Luxury Sober Living is honored to announce its nomination for the prestigious Best Luxury Sober Living in Los Angeles for 2024 . This acknowledgment reflects Haven House's unwavering dedication to offering a luxury sober living experience tailored to the needs of its residents.Haven House is renowned for blending structured recovery support with luxury amenities. By providing a safe and nurturing environment, Haven House empowers...

Read more

Rancho BioSciences, LLC Awarded Great Place to Work(R) Certification for the Third Consecutive Year

December 12, 2024 9:00 AM

Rancho BioSciences, LLC, the leading Data Science Services company headquartered in San Diego, California, is thrilled to announce that it has been awarded the prestigious Great Place to Work® Certification for the third consecutive year. This recognition underscores Rancho BioSciences' commitment to fostering a positive and collaborative work environment, driven by the company's mission to save lives through data.Receiving the Great Place to...

Read more

Mentavi Health Adds Sleep Coach Amanda Chocko to Support Its Comprehensive Mental Health Services

December 12, 2024 9:00 AM

GRAND RAPIDS, MI / ACCESSWIRE / December 4, 2024 / Nearly 37% of U.S. adults - more than one out of every three people - get too little sleep each day. Sleep disorders are also correlated with many mental health conditions: For example, up to 75% of people with ADHD (Attention-deficit/hyperactivity disorder) also have trouble getting enough sleep. Those statistics illustrate why Mentavi Health is pleased to add sleep coach Amanda Chocko to its...

Read more

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

December 12, 2024 9:00 AM

SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients...

Read more

Cellev8 Nutrition Launches the First GLP1 Support Gummy With Clinically Tested Ingredients

December 12, 2024 9:00 AM

Cellev8 Nutrition Inc., the innovative company behind the groundbreaking Cellev8 brand of patent pending wellness products, proudly announces the launch of "SlimCell™" - a revolutionary gummy formulated for post GLP-1 support, maintenance, and comprehensive weight management. While GLP-1 receptor agonist medications like Ozempic, Semaglutide, and Wegovy have transformed the weight loss landscape, SlimCell™ offers a complementary, all-natural...

Read more

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

December 12, 2024 8:30 AM

MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced it has raised $1 million in equity funding through The Starwood Trust. The investment, structured as a straightforward common stock transaction, was made at $7 per share representing a 20% premium to the closing price on the date of execution and included no warrants....

Read more

GAT Sport(R) Unveils Nitraflex(R) SPORT: The Next Evolution in Pre-Workout Power, Now Banned Substance-Tested and Certified by Informed Sport

December 12, 2024 8:15 AM

With its clinically dosed ingredients and Informed Sport certification, Nitraflex® SPORT is safer for athletes and designed for all fitness enthusiasts who demand high performance without the worry of banned substances. This powerful pre-workout enables users to push through their toughest sessions, exemplifying the brand's mantra to COMPETE HARDER®.Nitraflex® SPORT is now available on GATsport.com and Amazon, with plans to expand into global...

Read more

180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

December 12, 2024 8:00 AM

PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the...

Read more

Interactive Strength Inc. (Nasdaq:TRNR) Signs Exclusive Letter of Intent to Acquire Scaled and Profitable, Connected-Fitness Equipment Business

December 12, 2024 7:00 AM

Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or "the Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced that the Company has signed a non-binding letter of intent and exclusivity agreement to acquire a connected-fitness equipment company. The proposed transaction is expected to close as early as the first quarter of 2025 and be accretive to TRNR's financial results.For more commentary,...

Read more

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

December 12, 2024 7:00 AM

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb...

Read more

Action Behavior Centers and Non-Profit 29 Acres Announce Community Partnership to Empower Adults with Autism

December 11, 2024 7:00 PM

Action Behavior Centers (ABC), a provider of Applied Behavior Analysis (ABA) therapy for children with autism, is pleased to announce a partnership with a local, nonprofit organization, 29 Acres, dedicated to enriching the lives of adolescents and adults with autism. This collaboration will focus on creating meaningful employment opportunities and fostering independence for adults on the autism spectrum.A Vision for Inclusive Employment Through...

Read more

Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

December 11, 2024 4:00 PM

Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of...

Read more

Dr. Robert MacArthur Publishes Personal Blog Highlighting the Vital Role of Empathy in Orthopedic Surgery

December 11, 2024 3:50 PM

Esteemed orthopedic surgeon Dr. Robert MacArthur, MD, has published a new personal blog titled "Empathy in Orthopedic Surgery: Bridging Technical Skill and Patient Connection" to highlight the critical role of empathy in providing exceptional patient care. With over 20 years of experience in the field, Dr. MacArthur shares his insights into how understanding patients' emotional and physical challenges can transform surgical outcomes and improve...

Read more

Electromedical Technologies Unveils Groundbreaking Details About the WellnessPro Infinity and Announces Production Timeline

December 11, 2024 3:00 PM

Electromedical Technologies, Inc. (OTC PINK:EMED) - Electromedical Technologies is excited to share key updates on the WellnessPro Infinity, a revolutionary device redefining the standards of pain management and wellness technology. With production set to ramp up in early 2025, the WellnessPro Infinity is poised to deliver unparalleled precision and performance, setting a new benchmark in its class.A Journey of InnovationAt the heart of the...

Read more

Nanomerics Reports First Volunteers Dosed in the OC134 SUNLIGHT Trial

December 11, 2024 2:15 PM

LONDON, UK / ACCESSWIRE / December 11, 2024 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that dosing had commenced in its OC134 Phase I trial - the SUNLIGHT trial. Following approval in November 2024 from the UK Medicinal and Healthcare Products Regulatory Agency (MHRA), dosing of the first volunteers with both Nanomerics' MET eye drops and OC134 eye drops, took place this week. The clinical testing of...

Read more

Nature's Answer Awards $10,000 Grant to Support Local Individual Battling Breast Cancer

December 11, 2024 2:00 PM

Nature's Answer, a trusted leader in natural health solutions since 1972, is proud to announce that in November 2024, Vanessa Rosario was selected as the recipient of the Nature's Answer Breast Cancer Support Grant. Vanessa was granted $10,000 to assist with medical and personal expenses during her journey to recovery.The Nature's Answer Breast Cancer Support Grant was created to provide critical financial assistance to a breast cancer patient,...

Read more

Cantargia and GEICAM Present Updated Phase 1 Clinical Data and New Translational Results on Nadunolimab Treatment in Advanced Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium

December 11, 2024 1:45 PM

LUND, SWEDEN / ACCESSWIRE / December 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported updated results from the phase 1b study in 15 advanced triple negative breast cancer (aTNBC) patients treated with nadunolimab combined with platinum-based chemotherapy. The results confirm previous positive findings on safety, and promising antitumor activity. The clinical results along with new biomarker studies...

Read more

Quest Diagnostics Strengthens Supply Chain Management With Enhanced ESG Risk Assessment, Supplier Diversity, and Commitment to Ethical Standards

December 11, 2024 1:20 PM

NORTHAMPTON, MA / ACCESSWIRE / December 11, 2024 / Quest DiagnosticsOriginally published in Quest Diagnostics' 2023 Corporate Responsibility ReportCreating a healthier world requires collaboration, both across our internal team and with our global suppliers. Our suppliers allow us to provide the high-quality care and testing that our patients rely on. That's why we hold them to the same standards of ethics and integrity that we adhere to. We...

Read more

UK Clinicians Call for Urgent Modernization of NHS EHR Systems to Align With Global Healthcare IT Advancements, Black Book Survey Finds

December 11, 2024 11:30 AM

Over the past eleven months, Black Book Research conducted an extensive series of global surveys as part of the 2025 Black Book of Global Healthcare IT, uncovering widespread dissatisfaction among clinicians and hospital staff with Electronic Health Record (EHR) systems across the NHS in Scotland, England, and Wales. These findings expose critical challenges while presenting actionable strategies to enhance user satisfaction and EHR performance....

Read more